Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin effect on bladder wall thickness and urinary nerve growth factor in female overactive bladder
2008-005215-17Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of solifenacin in overactive bladder (OAB) (3 arms), sponsored by Astellas Pharma. Primary endpoint: Change in bladder wall thickness at 12 weeks. Started Aug 2009; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2008-005215-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005215-17.